V. Pulito

发表

Activation of estrogen receptor-β regulates hippocampal synaptic plasticity and improves memory

M. Day, K. Marquis, S. Grauer, 2008, Nature Neuroscience.

Novel heterocycles as selective α1-adrenergic receptor antagonists

L. Jolliffe, V. Pulito, W. Murray, 2000 .

Novel arylpiperazines as selective α 1 -adrenergic receptor antagonists

L. Jolliffe, V. Pulito, W. Murray, 2000 .

Arylpiperazine substituted heterocycles as Selective α1a adrenergic antagonists

L. Jolliffe, V. Pulito, G. Kuo, 2002 .

Novel thiophene derivatives for the treatment of benign prostatic hyperplasia.

L. Jolliffe, V. Pulito, W. Murray, 2002, Bioorganic & medicinal chemistry letters.

Humanization of the murine anti-human CD3 monoclonal antibody OKT3.

A. Collins, M. Bodmer, V. Pulito, 1994, Human antibodies and hybridomas.

In vitro characterization of five humanized OKT3 effector function variant antibodies.

P. Parren, J. Bluestone, A. Collins, 2000, Cellular immunology.

Synthesis, In Vitro Activities of (2-Cyclopropoxyphenyl)piperidine Derivatives for α1a and α1d Adrenergic Receptor Inhibitors

P. Connolly, S. Middleton, V. Pulito, 2009 .

(Phenylpiperidinyl)cyclohexylsulfonamides: development of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).

P. Connolly, S. Middleton, V. Pulito, 2007, Bioorganic & medicinal chemistry letters.

Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.

J. Bluestone, W. Olson, A. Collins, 1992, Journal of immunology.

Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes

T. Comery, S. Grauer, J. Brennan, 2010, Proceedings of the National Academy of Sciences.

A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions

Samuel A. Williams, O. Foord, M. Aujay, 2017, Science Translational Medicine.

Design, synthesis and biological evaluation of pyridine-phenylpiperazines: a novel series of potent and selective alpha1a-adrenergic receptor antagonist.

L. Jolliffe, C. Prouty, V. Pulito, 2000, Bioorganic & medicinal chemistry.

An Investigation of the Uroselective Properties of Four Novel α1a-Adrenergic Receptor Subtype-Selective Antagonists

L S Mulcahy, L. Jolliffe, A. Reitz, 2000 .

1-Arylpiperazinyl-4-cyclohexylamine derived isoindole-1,3-diones as potent and selective alpha-1a/1d adrenergic receptor ligands.

P. Connolly, S. Middleton, V. Pulito, 2007, Bioorganic & medicinal chemistry letters.

Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia

T. Comery, U. Egerland, M. Malamas, 2009, Journal of Pharmacology and Experimental Therapeutics.

Phosphodiesterase 10 A Inhibitor Activity in Preclinical Models of the Positive , Cognitive , and Negative Symptoms of Schizophrenia

T. Comery, U. Egerland, M. Malamas, 2009 .

The psychiatric disease risk factors DISC1 and TNIK interact to regulate synapse composition and function

A. Hayashi‐Takagi, Zhen Yan, R. Weinberg, 2011, Molecular Psychiatry.

Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions

Kathryn Loving, O. Foord, M. Aujay, 2015, Clinical Cancer Research.

DNA fragments in Friend erythroleukemia cells induced by dimethyl sulfoxide.

S. Sassa, V. Pulito, T. Yamane, 1983, Proceedings of the National Academy of Sciences of the United States of America.

The orphan GPCR, GPR88, modulates function of the striatal dopamine system: A possible therapeutic target for psychiatric disorders?

K. Marquis, S. Grauer, Radka Graf, 2009, Molecular and Cellular Neuroscience.

Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists.

L. Jolliffe, V. Pulito, W. Murray, 2000, Bioorganic & medicinal chemistry letters.

α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms

P. Connolly, S. Middleton, A. Reitz, 2008 .

(Phenylpiperazinyl)cyclohexylureas: discovery of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).

P. Connolly, S. Middleton, V. Pulito, 2008, Bioorganic & medicinal chemistry letters.

Aminocyclohexylsulfonamides: discovery of metabolically stable alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).

P. Connolly, S. Middleton, Sean X Peng, 2007, Bioorganic & medicinal chemistry letters.

(Arylpiperazinyl)cyclohexylsufonamides: discovery of alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS).

P. Connolly, S. Middleton, V. Pulito, 2007, Bioorganic & medicinal chemistry letters.

Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.

L. Jolliffe, C. Prouty, V. Pulito, 2000, Journal of medicinal chemistry.

Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A.

V. Roberts, A. Collins, R. Zivin, 1996, Journal of immunology.

The orphan GPCR, GPR88, modulates function of the striatal dopamine system: A possible therapeutic target for psychiatric disorders?

K. Marquis, S. Grauer, Radka Graf, 2009, Molecular and Cellular Neuroscience.